[1]黄玉斌,刘　霄,徐翠香,等.胃癌干细胞和免疫检查点抑制剂治疗胃癌研究进展[J].新乡医学院学报,2022,39(5):486-490.[doi:10.7683/xxyxyxb.2022.05.017]
　HUANG Yubin,LIU Xiao,XU Cuixiang,et al.Research progress of gastric cancer stem cells and immune checkpoint inhibitors therapy for gastric cancer[J].Journal of Xinxiang Medical University,2022,39(5):486-490.[doi:10.7683/xxyxyxb.2022.05.017]
点击复制

胃癌干细胞和免疫检查点抑制剂治疗胃癌研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年5
页码:
486-490
栏目:
综述
出版日期:
2022-05-05

文章信息/Info

Title:
Research progress of gastric cancer stem cells and immune checkpoint inhibitors therapy for gastric cancer
作者:
黄玉斌1; 2; 刘　霄1; 2; 徐翠香3; 黄晓燕3; 王建华2
（1.西安医学院，陕西　西安　710021；2.陕西省人民医院普外二科，陕西　西安　710068；3.陕西省人民医院陕西省感染与免疫疾病重点实验室，陕西　西安　710068）
Author(s):
HUANG Yubin1; 2; LIU Xiao1; 2; XU Cuixiang3; HUANG Xiaoyan3; WANG Jianhua2
（1.Xi′an Medical University,Xi′an 710021,Shaanxi Province,China;2.The Second Department of General Surgery,Shaanxi Provincial People′s Hospital,Xi′an 710068,Shaanxi Province,China;3.Shaanxi Key Laboratory of Infection and Immune Diseases,Shaanxi Provincial People′s Hospital,Xi ′an 710068,Shaanxi Province,China）
关键词:
胃癌; 胃癌干细胞; 免疫治疗; 免疫检查点抑制剂
Keywords:
gastric cancer; gastric cancer stem cell; immunotherapy; immune checkpiont inhibitor
分类号:
R735.2
DOI:
10.7683/xxyxyxb.2022.05.017
文献标志码:
A
摘要:
胃癌是全球最常见的恶性肿瘤之一。胃癌患者采用传统的手术、放射治疗、化学治疗临床获益有限，5 a生存率不甚理想。近年来，程序性死亡受体-1/程序性死亡受体配体-1抑制剂联合细胞毒性T 淋巴细胞相关蛋白 4抑制治疗胃肿瘤的研究较多且取得了重大进展，已成为胃癌治疗的一种新手段。肿瘤干细胞在胃癌的发生、发展过程中发挥着至关重要的作用，其富聚多种肿瘤特异性抗原及特异性分子标志物，靶向肿瘤干细胞，可产生有效的抗肿瘤效应。免疫治疗已在多种肿瘤的研究中取得进展，在胃癌治疗中也获得了突破，其可能是临床上治疗胃癌的一种有效策略。本研究就近年来胃癌干细胞及免疫检查点抑制剂治疗胃癌的研究进展作一综述。
Abstract:
Gastric cancer is one of the most common malignant tumors in the world.The clinical benefits of traditional surgery,radiotherapy and chemotherapy in patients with gastric cancer are limited,and the 5-year survival rate is not ideal.In recent years,there have been many studies on programmed death receptor-1/programmed death receptor ligand-1 inhibitor combined with cytotoxic T lymphocyte associated protein 4 inhibitor for gastric tumors and made great progress,and it has become an effective new method for the treatment of gastric cancer.Gastric stem cells play a vital role in the occurrence and development of gastric cancer.Gastric cancer stem cells accumulate a variety of tumor-specific antigens and specific molecular markers,targeting cancer stem cells,which can produce effective anti-cancer drugs.Immunotherapy has made great progress in the research of many kinds of tumors and made a breakthrough in the treatment of gastric cancer.It may be an effective strategy for clinical treatment of gastric cancer.This study reviewed the research progress of gastric cancer stem cells and immune checkpoint inhibitors for gastric cancer in recent years.

参考文献/References:

［1］　COBURN N,COSBY R,KLEIN L,et al.Staging and surgical approaches in gastric cancer:a systematic review［J］.Cancer Treat Rev,2018,63:104-115.
［2］　BAKHSHINYAN D,ADILE A A,QAZI M A,et al.Introduction to cancer stem cells:past,present,and future［J］.Methods Mol Biol,2018,1692:1-16.
［3］　DASHTI A,EBRAHIMI M,HADJATI J,et al.Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses［J］.Cancer Lett,2016,374(1):175-185.
［4］　HU Y,LU L,XIA Y,et al.Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting［J］.Cancer Res,2016,76(16):4661-4672.
［5］　ZHENG F,DANG J,ZHANG H,et al.Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model［J］.J Immunother,2018,41(8):361-368.
［6］　STOJNEV S,KRSTIC M,RRSTIC-PETROVIC A,et al.Gastric cancer stem cells:therapeutic targets［J］.Gastric Cancer,2014,17(1):13-25.
［7］　YANG L,PING Y F,YU X,et al.Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype［J］.Cancer Lett,2011,310(1):46-52.
［8］　ABBASZADEGAN M R,BAGHERI V,RAZAVI M S,et al.Isolation,identification,and characterization of cancer stem cells:a review［J］.J Cell Physiol,2017,232(8):2008-2018.
［9］　BAGHERI V,ABBASZADEGAN M R,MEMAR B,et al.Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer［J］.Life Sci,2019,219:136-143.
［10］　KIM T M,KO Y H,HA S J,et al.Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers［J］.BMC Cancer,2019,19(1):119.
［11］　贾荣保,姜立新,姚增武,等.碳纳米材料在胃癌治疗中的应用进展［J］.中国普外基础与临床杂志,2018,25(4):499-504.
JIA R B,JIANG L X,YAO Z W,et al.Application advances of carbon nanomaterial in therapy for gastric cancer［J］.Chin J Bas Clin Gen Surg,2018,25(4):499-504.
［12］　刘亚军.基于肿瘤CD44受体靶向的小分子自组装纳米复合物的制备及其抗肿瘤作用研究［D］.福州:福州大学,2017.
LIU Y J.Preparation and antitumor activity of small molecule self-assembled nanocomposites based on tumor CD44 receptor targeting［D］.Fuzhou:Fuzhou University,2017.
［13］　SMITH L M,NESSTEROVA A,RYAN M C,et al.CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers［J］.Br J Cancer,2008,99(1):100-109.
［14］　JIANG J,ZHANG Y,CHUAI S,et al.Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype［J］.Oncogene,2012,31(6):671-82.
［15］　GAO Y,CAI A,XI H,et al.Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-β/catenin signaling pathway［J］.Stem Cell Res Ther,2017,8(1):1-11.
［16］　SONG Z,YUE W,WEI B,et al.Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer［J］.PLoS One,2011,6(3):e17687.
［17］　MAO J,FAN S,MA W,et al.Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment［J］.Cell Death Dis,2014,5(1):e1039.
［18］　FAN D,REN B,YANG X,et al.Upregulation of miR-501-5p activates the Wnt/β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer［J］.J Exp Clin Cancer Res,2016,35(1):177.
［19］　JIANG Y Q,GUO Q M,XU X P,et al.Preparation of chaperone-antigen peptide vaccine derived from human gastric cancer stem cells and its immune function［J］.Chin J Oncol,2017,39(2):109-114.
［20］　RIBAS A,WOLCHOK J D.Cancer immunotherapy using checkpoint blockade［J］.Science,2018,359(6382):1350-1355.
［21］　TAIEB J,MOEHLER M,BOKU N,et al.Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers:current status and future perspectives［J］.Cancer Treat Rev,2018,66:104-113.
［22］　ARASANZ H,GATO-CANAS M,ZUAZO M,et al.PD-1 signal transduction pathways in T cells［J］.Oncotarget,2017,8(31):51936-51945.
［23］　KUOL N,STOJANOVSKA L,NURGALI K,et al.PD-1/PD-L1 in disease［J］.Immunotherapy,2018,10(2):149-160.
［24］　HOSSEINZADEH F,MOHAMMADI S,NEJATOLLAHI F.Production and evaluation of specific single-chain antibodies against CTLA-4 for cancer-targeted therapy［J］.Rep Biochem Mol Biol,2017,6(1):8-14.
［25］　BAUMEISTER S H,FREEMAN G J,DRANOFF G,et al.Coinhibitory pathways in immunotherapy for cancer［J］.Annu Rev Immunol,2016,34:539-573.
［26］　JOSEPH R W,SHILLINGTON A C,LEE T A,et al.Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers［J］.J Med Econ,2020,23(2):132-138.
［27］　FUCHS C S,DOI T,JANG R W,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical keynote-059 trial［J］.JAMA Oncol,2018,4(5):e180013.
［28］　葛柯乐,方成,吴骏.胃癌中免疫检查点抑制剂应用的研究进展［J］.临床肿瘤学杂志,2019,24(11):1050-1054.
GE K L,FANG C,WU J.Research progress on the application of immune checkpoint inhibitors in gastric cancer［J］.Chin Clin Oncol,2019,24 (11):1050-1054.
［29］　MURO K,CHUNG H C,SHANKARAN V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012):a multicentre,open-label,phase 1b trial［J］.Lancet Oncol,2016,17(6):717-726.
［30］　KITANO S.Development of immune checkpoint inhibitors［J］.Rinsho Ketsueki,2017，58(8):966-976.
［31］　KANG Y K,BOKU N,SATOH T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens (ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet,2017,390(10111):2461-2471.
［32］　HEERY C R,O′SULLIVAN-COYNE G,MADAN R A,et al.Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor):a phase 1a,multicohort,dose-escalation trial［J］.Lancet Oncol,2017,18(5):587-598.
［33］　CHUNG H C,ARKENAU H T,LEE J,et al.Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer:phase 1b results from the JAVELIN solid tumor trial［J］.J Immunother Cancer,2019,7(1):30.
［34］　张凯利,隋红.胃癌免疫治疗的研究进展［J］.肿瘤学杂志,2019,25(8):685-690.
ZHANG K L,SUI H.Research progress of immunotherapy for gastric cancer［J］.Chin J Oncol,2019,25(8):685-690.
［35］　RALPH C,ELKORD E,BURT D J,et al.Modulation of lymphocyte regulation for cancer therapy:a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma［J］.Clin Cancer Res,2010,16(5):1662-1672.
［36］　姚洋,张艳桥.胃癌免疫检查点抑制剂作用机制及最新研究进展［J］.实用肿瘤学杂志,2019,33(4):371-375.
YAO Y,ZHANG Y Q.Mechanism and recent research progress of immune checkpoint inhibitors in gastric cancer［J］.Pract Oncol J,2019,33(4):371-375.
［37］　BANG Y J,CHO J Y,KIM Y H,et al.Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer［J］.Clin Cancer Res,2017,23(19):5671-5678.
［38］　ROTTE A.Combination of CTLA-4 and PD-1 blockers for treatment of cancer［J］.J Exp Clin Cancer Res,2019,38(1):255.
［39］　RIBAS A,WOLCHOK J D.Cancer immunotherapy using checkpoint blockade［J］.Science,2018,359(6382):1350-1355.
［40］　JANJIGIAN Y Y,BENDELL J,CALVO E,et al.CheckMate-032 study:efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer［J］.J Clin Oncol,2018,36(28):2836-2844.
［41］　KELLY R J,LEE J,BANG Y J,et al.Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma［J］.Clin Cancer Res,2020,26(4):846-854.
［42］　ZHANG X,SHI X,LI J,et al.PD-1 blockade overcomes adaptive immune resistance in treatment with anchored-GM-CSF bladder cancer cells vaccine［J］.J Cancer,2018,9(23):4374-4381.
［43］　SUN L,WANG Q,CHEN B,et al.Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis［J］.Cell Death Dis,2018,9(9):928.

相似文献/References:

[1]陈赜,陈杰,严想元,等.腹腔镜辅助胃癌根治术治疗早期胃癌疗效观察[J].新乡医学院学报,,():000.
[2]于成功,萧树东,赵宪邨,等.胃癌胃良性病变患者血清和局部组织中IL—I水平及意义[J].新乡医学院学报,1996,13(03):220.
[3]王淑秀,赵卫星,和瑞芝,等.P~(53)和rasP~(21)在胃癌中表达的免疫组化研究[J].新乡医学院学报,1997,14(02):137.
[4]赵卫星,王淑秀,卢朝晖,等.幽门螺杆菌与胃癌基因抑癌基因突变的关系[J].新乡医学院学报,1997,14(03):203.
[5]王淑秀.抑癌基因和癌基因与胃癌[J].新乡医学院学报,1997,14(01):083.
[6]冯艳玲,乐晓萍,蔡新华.胃癌患者P16和P53蛋白的表达及其相互关系[J].新乡医学院学报,2000,17(06):403.
[7]周玲生.纤维胃镜粘膜活检1356 例病理分析[J].新乡医学院学报,2000,17(06):462.
[8]任金萍,王淑秀,付华民,等.青年与老年人胃癌中PCNA和AgNOR计数表达的对比研究[J].新乡医学院学报,2000,17(03):156.
[9]贾文英,张合喜,马彦民.幽门螺杆菌感染与胃癌关系的Meta 分析[J].新乡医学院学报,2000,17(05):328.
[10]窦天伟,刘 炯,罗志勇,等.复发胃癌再次手术42例疗效和随访结果[J].新乡医学院学报,2003,20(05):337.

更新日期/Last Update: 2022-05-05